FDA clears Great Smokies' intestinal permeability test:
This article was originally published in Clinica
Great Smokies Diagnostic Laboratory (GSDL) has received US FDA 510(k) clearance for its non-invasive test for measuring intestinal permeability, a measurement used to help diagnose gastrointestinal malabsorption syndromes, such as coeliac disease, Crohn's disease and irritable bowel syndrome. The intestinal permeability test kit is more sensitive than the existing d-xylose test, said the Asheville, North Carolina-based company, which also noted that it was the first commercial laboratory to offer intestinal permeability testing.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.